PARP1-IN-5 dihydrochloride?

CAS No. 2823308-89-8

PARP1-IN-5 dihydrochloride?( —— )

Catalog No. M37639 CAS No. 2823308-89-8

PARP1-IN-5 dihydrochloride is an orally active, potent and selective PARP-1 inhibitor (IC50 =14.7 nM). PARP1-IN-5 dihydrochloride can be used for the research of cancer.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 231 In Stock
5MG 188 In Stock
10MG 297 In Stock
25MG 591 In Stock
50MG 811 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    PARP1-IN-5 dihydrochloride?
  • Note
    Research use only, not for human use.
  • Brief Description
    PARP1-IN-5 dihydrochloride is an orally active, potent and selective PARP-1 inhibitor (IC50 =14.7 nM). PARP1-IN-5 dihydrochloride can be used for the research of cancer.
  • Description
    PARP1-IN-5 dihydrochloride is a low toxicity, orally active, potent and selective PARP-1 inhibitor (IC50 =14.7 nM). PARP1-IN-5 dihydrochloride can be used for the research of cancer.
  • In Vitro
    PARP1-IN-5 dihydrochloride (0.1~10 μM; A549 cells) can significantly increase the cytotoxicity of CBP on A549 cells in a dose-dependent manner. PARP1-IN-5 dihydrochloride (0.1~10 μM; SK-OV-3 cells) decreases the expressions of MCM2-7. PARP1-IN-5 dihydrochloride (0.1~320 μM; A549 cells) has little cytotoxic effects on A549 cells. PARP1-IN-5 dihydrochloride (SK-OV-3 cells) can significantly decrease the PAR level.PARP1-IN-5 dihydrochloride exerts antitumor effects through PARP-1. PARP1-IN-5 dihydrochloride could increase the γ-H2AX expression.
  • In Vivo
    PARP1-IN-5 dihydrochloride (1000 mg/kg; p.o.) shows that there is no significant difference in the body weight and blood routine.PARP1-IN-5 dihydrochloride (25 and 50 mg/kg; p.o.; 12 days) significantly enhances the inhibitory effect of carboplatin on A549 cells at 50 mg/kg.PARP1-IN-5 dihydrochloride (50 mg/kg; p.o.) positively correlates with the expression of PARP-1.PARP1-IN-5 dihydrochloride can upregulate the expression of γ-H2AX and decrease the expression of PAR.Animal Model:Mice Dosage:1000 mg/kg Administration:P.o.Result:There was no significant difference in the body weight and blood routine.Animal Model:Mice Dosage:25 and 50 mg/kg Administration:P.o.; 12 days Result:Significantly enhanced the inhibitory effect of CBP on A549 cells at 50 mg/kg.Animal Model:Male Sprague?Dawley (SD) rats Dosage:50 mg/kg (Pharmacokinetic Analysis)Administration:P.o.Result:Positively correlated with the expression of PARP-1.
  • Synonyms
    ——
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    PARP
  • Recptor
    PARP
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2823308-89-8
  • Formula Weight
    537.46
  • Molecular Formula
    C25H26Cl2N2O5S
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 125 mg/mL (232.58 mM; Ultrasonic )H2O : 1 mg/mL (1.86 mM; Ultrasonic (<60°C)
  • SMILES
    O=C1C=C(C2=CC=C(O)C=C2)OC3=C(CN4CCN(CC5=CC=CS5)CC4)C(O)=CC(O)=C31.Cl[H].Cl[H]
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Long H, et al. Discovery of Novel Apigenin-Piperazine Hybrids as Potent and Selective Poly (ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors for the Treatment of Cancer. J Med Chem. 2021;64(16):12089-12108.?
molnova catalog
related products
  • Desmethyl-VS-5584

    Desmethyl-VS-5584 is a dimethyl analog of VS-5584, which is a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer.

  • E7449

    E7449 (2X-121) is a potent, orally bioavailable, brain penetrable dual inhibitor of PARP1/2 and TNKS1/2 with IC50 of 2.0/1.0 nM (PARP1/2), 50-100 nM (TNKS1/2).

  • PARP10-IN-2

    PARP10-IN-2 is a potent inhibitor of PARP10, a mono-ADP-ribosyltransferase, with an IC50 value of 3.64 μM for human PARP10. It also inhibits PARP2 and PARP15, with IC50 values of 27 μM and 11 μM, respectively.